It has been reported that PARP inhibitors are more effective for patients with BRCA1- and BRCA2- mutant ovarian cancer than for breast cancers [5], which shows that genetic context is crucial for functional genomic target screening. This evidence concerns the gene PARP1 and ovarian carcinoma.